Dose-Finding Clinical Trials in Stan

Kristian Brock, StanCon Helsinki, 30-Aug-18


Phase I
Phase II
Phase III
Phase IV

What dose?

Not too toxic…but

High enough to be effective



What dose?

Not too toxic…but

High enough to be effective



Is it any good?

Does it do something desirable?

What dose?

Not too toxic...but

High enough to be effective

Pivotal study

The challenger vs the standard of care



Is it any good?

Does it do something desirable?

What dose?

Not too toxic...but

High enough to be effective

Pivotal study

The challenger vs the standard of care



Is it any good?

Does it do something desirable?

Post-marketing

We'll use it...

But let's keep an eye on it

Dose-finding by toxicity

Dose Finding and the 3+3 Method



Surely folk use statistical models these days?

- Chiuzan *et al.* (2017) conducted systematic review of dose-finding methods
- Cancer trials published between 2008 and 2014



"adoption of [model-based] designs continues to remain low"

Chiuzan, *et al.* (2017). Dose-finding designs for trials of molecularly targeted agents and immunotherapies. Journal of Biopharmaceutical Statistics, https://doi.org/10.1080/10543406.2017.1289952

Continual Reassessment Method (CRM)



O'Quigley, Pepe, and Fisher (1990). Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer. Biometrics. https://doi.org/10.2307/2531628.

Continual Reassessment Method (CRM)



O'Quigley, Pepe, and Fisher (1990). Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer. Biometrics. https://doi.org/10.2307/2531628.

Continual Reassessment Method (CRM)



O'Quigley, Pepe, and Fisher (1990). Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer. Biometrics. https://doi.org/10.2307/2531628.

Levy *et al.* - ssHHT in leukaemia



Levy, et al. (2006) A Phase I Dose-Finding and Pharmacokinetic Study of Subcutaneous Semisynthetic Homoharringtonine (ssHHT) in Patients with Advanced Acute Myeloid Leukaemia. BJC. https://doi.org/10.1038/sj.bjc.6603265.

Levy *et al.* - ssHHT in leukaemia



Levy, et al.(2006) A Phase I Dose-Finding and Pharmacokinetic Study of Subcutaneous Semisynthetic Homoharringtonine (ssHHT) in Patients with Advanced Acute Myeloid Leukaemia. BJC. https://doi.org/10.1038/sj.bjc.6603265.

Dose-finding by toxicity & efficacy

Dose-toxicity & efficacy in modern therapies





Brock, *et al.* (unpublished). Meta-analysis of the dose-toxicity and dose-efficacy curves in the manuscripts in the Chiuzan (2017) review paper.

EffTox - dose-finding based on efficacy & toxicity trade-offs



Thall, PF, and JD Cook. (2004) Dose-Finding Based on Efficacy-Toxicity Trade-Offs. Biometrics 60, no. 3 (2004): 684–93.

Posterior beliefs on attractiveness

Prob("dose in column is more attractive than dose in row")

Dose	1	2	3	4	5
1		0.92	0.86	0.82	0.8
2			0.75	0.68	0.64
3				0.58	0.54
4					0.52
5					

trialr - clinical trial designs in R & Stan

```r

# Install
devtools::install_github('brockk/trialr')
# Or
install.packages('trialr')

# CRM
levy ← '1NNN 3NNT 4NNT 4NNN 4NTN 4TNT'
skeleton ← c(0.05, 0.10, 0.15, 0.33, 0.5)
target ← 0.33
levy_mod ← stan_crm(levy, skeleton = skeleton, target = target,
                    model = 'logistic_gamma', a0 = 4,
                    beta_shape = 1, beta_inverse_scale = 1,
                    seed = 123, control = list(adapt_delta = 0.95))

# EffTox
outcomes ← '1NEN 2NBE'
mod2 ← stan_efftox_demo(outcomes, seed = 123)
# That is short-hand for
mod2 ← stan_efftox(outcomes,
                   real_doses = c(1.0, 2.0, 4.0, 6.6, 10.0),
                   efficacy_hurdle = 0.5, toxicity_hurdle = 0.3,
                   p_e = 0.1, p_t = 0.1,
                   eff0 = 0.5, tox1 = 0.65,
                   eff_star = 0.7, tox_star = 0.25,
                   alpha_mean = -7.9593, alpha_sd = 3.5487,
                   beta_mean = 1.5482, beta_sd = 3.5018,
                   gamma_mean = 0.7367, gamma_sd = 2.5423,
                   zeta_mean = 3.4181, zeta_sd = 2.4406,
                   eta_mean = 0, eta_sd = 0.2,
                   psi_mean = 0, psi_sd = 1,
                   seed = 123)

```

Future work:

- Add more trial designs :-)
- Plumb it to work with tidybayes
- More visualisation via bayesplot
- Scrutinise fit by shinystan, etc
- Automated documents via Flexdashboards?

The End

Kristian Brock
Senior Biostatistician
Cancer Research UK Clinical Trials Unit
University of Birmingham
k.brock@bham.ac.uk or
kristian.brock@gmail.com

Cancer Research UK Clinical Trials Unit @CRCTU

Institute of Translational Medicine Birmingham

UNIVERSITY OF BIRMINGHAM